Louisiana State Employees Retirement System Increases Stake in Haemonetics Corp. (HAE)
Louisiana State Employees Retirement System raised its stake in shares of Haemonetics Corp. (NYSE:HAE) by 0.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,600 shares of the company’s stock after buying an additional 100 shares during the period. Louisiana State Employees Retirement System’s holdings in Haemonetics Corp. were worth $655,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the stock. BlackRock Inc. raised its position in Haemonetics Corp. by 125.7% in the first quarter. BlackRock Inc. now owns 3,501 shares of the company’s stock valued at $122,000 after buying an additional 1,950 shares during the last quarter. Invictus RG raised its position in shares of Haemonetics Corp. by 20.1% in the first quarter. Invictus RG now owns 4,074 shares of the company’s stock worth $143,000 after buying an additional 681 shares in the last quarter. Kirr Marbach & Co. LLC IN purchased a new position in shares of Haemonetics Corp. during the second quarter worth approximately $210,000. Fox Run Management L.L.C. raised its position in shares of Haemonetics Corp. by 3.8% in the second quarter. Fox Run Management L.L.C. now owns 8,200 shares of the company’s stock worth $238,000 after buying an additional 300 shares in the last quarter. Finally, First Quadrant L P CA purchased a new position in shares of Haemonetics Corp. during the second quarter worth approximately $342,000. Institutional investors and hedge funds own 98.64% of the company’s stock.
Shares of Haemonetics Corp. (NYSE:HAE) traded down 0.88% during midday trading on Thursday, hitting $36.12. 334,802 shares of the company were exchanged. The stock’s 50-day moving average is $36.81 and its 200-day moving average is $32.58. The stock’s market cap is $1.85 billion. Haemonetics Corp. has a one year low of $25.98 and a one year high of $38.06.
Haemonetics Corp. (NYSE:HAE) last posted its earnings results on Monday, August 1st. The company reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by $0.03. Haemonetics Corp. had a negative net margin of 7.25% and a positive return on equity of 10.75%. The firm earned $210 million during the quarter, compared to analyst estimates of $205.41 million. During the same quarter in the previous year, the business posted $0.35 earnings per share. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. Equities research analysts anticipate that Haemonetics Corp. will post $1.44 EPS for the current year.
A number of equities analysts have commented on HAE shares. Jefferies Group boosted their price objective on shares of Haemonetics Corp. from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Benchmark Co. boosted their price objective on shares of Haemonetics Corp. from $28.00 to $32.00 and gave the stock a “hold” rating in a report on Tuesday, August 2nd. Zacks Investment Research upgraded shares of Haemonetics Corp. from a “strong sell” rating to a “hold” rating in a report on Monday, July 4th. Barrington Research lowered shares of Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 3rd. Finally, CJS Securities lowered shares of Haemonetics Corp. from a “market outperform” rating to a “market perform” rating and set a $35.00 price objective on the stock. in a report on Tuesday, September 20th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $34.50.
In related news, CEO Christopher Simon purchased 60,000 shares of Haemonetics Corp. stock in a transaction on Thursday, August 4th. The stock was purchased at an average cost of $35.00 per share, with a total value of $2,100,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ronald Merriman sold 4,337 shares of the stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $35.14, for a total transaction of $152,402.18. Following the completion of the sale, the director now directly owns 22,088 shares of the company’s stock, valued at $776,172.32. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.
Haemonetics Corp. Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corp. (NYSE:HAE).
Receive News & Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.